Policy and Politics

European elections threaten political quagmire for TPD

30th May 2014 - News analysis |

The process of drawing up detailed rules on e-cigarettes to implement the new European Tobacco Products Directive (TPD) could become mired in political disagreements, following a European Parliament election which has fragmented power in Brussels.

WHO told to go easy on e-cigs, consider health benefits

29th May 2014 - News analysis |

The World Health Organization (WHO) has been urged to adopt a gentle touch on regulation of e-cigarettes in a letter this week signed by more than 50 nicotine science and public health specialists, apparently hoping to head off the prospect of tobacco-style rules.

FDA lambasted over comments process, inaction on flavours

18th May 2014 - News analysis |

The U.S. Food and Drug Administration (FDA) is reviewing requests to extend the public comment period on its proposal to regulate e-cigarettes as tobacco products, a senior FDA official told a a key U.S. Senate committee on Thursday, drawing a decidedly mixed response from the panel’s top Democrat and Republican alike.

Laying down the law: regulation to dominate industry confabs

14th May 2014 - News analysis |

E-cigarettes are on the agenda for a host of trade and professional conferences over the coming weeks, reflecting the urgent need for understanding of new regulatory measures as well as the sector’s development and improving scientific knowledge about the products.

U.S. senators bid to ban vaping in the corridors of D.C. power

8th May 2014 - News analysis |

The world’s most powerful deliberative body has been asked to decide a question that sounds both simple and modern: to vape or not to vape. But leading Democrats – whose party currently holds power in the U.S. Senate – are once again discovering just how deliberative that august body can be.

U.S. media on deeming regs: FDA tries hard, could do better

1st May 2014 - News analysis |

The proposed new e-cigarette regulations from the U.S. Food and Drug Administration (FDA) received a lukewarm welcome from the country’s mainstream media, with most editorialists backing the agency’s restrictions but suggesting it will have to go further.

SEC (Sociedad Española de Cardiología) (Spanish Society of Cardiology)

30th April 2014 - Resources |

The SEC does not recommend e-cigarettes as a valid way to quit conventional tobacco and would like to see emergency regulation and control implemented. www.secardiologia.es/ Calle de Nuestra Señora de Guadalupe, Nº 5 y 7
Madrid
28028, España)
Teléfono: 91 724 23 70
Fax: 91 724 23 71 Contact via online form

FDA’s product approval process is biggest worry for e-cig sector

25th April 2014 - News analysis |

The deeming regulations on e-cigarettes issued yesterday by the U.S. Food and Drug Administration (FDA) were largely expected by the industry and greeted without panic, although concerns were raised over the product approval process and the underlying philosophy of regulating all nicotine-containing products in a similar way.

New FDA rules and Europe’s directive: how do they compare?

25th April 2014 - News analysis |

The new regulations for e-cigarettes proposed yesterday by the U.S. Food and Drug Administration (FDA) are the second major regulatory framework for the products to appear in two months, following the European Union’s release of its revised Tobacco Products Directive (TPD) earlier this year. How do the two compare in key areas?

EU will not publish detailed guidance on TPD e-cig rules

23rd April 2014 - News analysis |

The European Union (EU) does not plan to issue detailed guidance on how e-cigarette regulations in the recent Tobacco Products Directive (TPD) should be interpreted, according to a source close to the EU’s Directorate General for Health and Consumer Affairs (SANCO)

Could EU directive be a model
for U.S. treatment of e-cigs?

16th April 2014 - News analysis |

The European Parliament’s new rules on e-cigarettes in the Tobacco Products Directive (TPD) have grabbed the attention of key members of the U.S. Senate, generating mixed reactions on whether it should influence the efforts of the Food and Drug Administration (FDA) to regulate the products.